Arcturus Therapeutics Holdings Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARCT Nasdaq 2836 arcturusrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcturus Therapeutics Holdings Inc.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - Mar 25th, 2026 9:12 am
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf - Mar 23rd, 2026 12:47 pm
These Are the Only 3 Stocks That Cathie Wood Bought Last Week - Mar 23rd, 2026 5:27 am
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing - Mar 12th, 2026 12:02 am
Arcturus Therapeutics to Attend Upcoming Investor Conference - Mar 5th, 2026 7:00 am
Arcturus Therapeutics Holdings Inc. Q4 2025 Earnings Call Summary - Mar 4th, 2026 6:02 pm
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call Highlights: Navigating Revenue ... - Mar 3rd, 2026 10:01 pm
Arcturus Therapeutics Q4 Earnings Call Highlights - Mar 3rd, 2026 4:02 pm
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates - Mar 3rd, 2026 3:10 pm
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress - Mar 3rd, 2026 2:01 pm
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates - Mar 2nd, 2026 6:15 am
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates - Feb 26th, 2026 11:30 am
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026 - Feb 17th, 2026 2:01 pm
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) In A Good Position To Deliver On Growth Plans? - Feb 16th, 2026 4:24 am
Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit - Feb 11th, 2026 10:52 am
Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating - Feb 9th, 2026 12:14 pm
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets - Feb 2nd, 2026 7:54 am
Arcturus Therapeutics Holdings (ARCT) Valuation Check As J.P. Morgan Healthcare Conference Presentation Nears - Jan 13th, 2026 2:16 pm
Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference - Jan 12th, 2026 8:06 pm
Is Arcturus Therapeutics (ARCT) Using Its $500 Million Shelf to Redefine Capital Strategy? - Jan 12th, 2026 12:08 pm